TARS - Tarsus Pharma stock climbs 15% on positive TP-03 data in late-stage study of ocular disease

Tarsus Pharmaceuticals (TARS) soars 15% premarket after announcing that all pre-specified primary and secondary endpoints were met for its Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis.Demodex blepharitis is characterized by inflammation of the eyelid margin, redness and ocular irritation. Results demonstrated 81% of patients achieved a significant, clinically meaningful collarette cure defined by a collarette grade of zero (0) or one (1) at day 43 compared to 23% of those on vehicle (p<0.0001).Additionally, a significant, clinically meaningful collarette cure was seen in 23% of patients on TP-03 compared to 11% on vehicle as early as day 8 (p=0.0003).Saturn-1 data also showed that 43% of patients on TP-03 achieved the primary endpoint of complete collarette cure (grade 0) at day 43, defined as zero to two (0-2) collarettes per lid compared to 7% on vehicle (p<0.0001).The Saturn-1 trial also met the secondary endpoints of mite eradication

For further details see:

Tarsus Pharma stock climbs 15% on positive TP-03 data in late-stage study of ocular disease